WZ4003 sensitizes non-small cell lung cancer cells to gefitinib via inhibition of ARK5 and epithelial-to-mesenchymal transition

Gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, is used as a first-line treatment for advanced non-small cell lung cancer (NSCLC); however, its utility is hampered by the development of chemoresistance. This study aimed to investigate the synergistic role of WZ4003, a novel...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Am J Transl Res
Egile Nagusiak: Chen, Jiabin, Zhang, Shufen, Zheng, Xiaoxiao, Mao, Jiayan, Xie, Shangzhi, Chen, Wei, Ran, Xiangui
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: e-Century Publishing Corporation 2020
Gaiak:
Original Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7724321/
https://ncbi.nlm.nih.gov/pubmed/33312374
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak